Abstract

Metastatic castration-resistant prostate cancer (mCRPC) remains a terminal diagnosis with an aggressive disease course despite currently approved therapeutics. The recent successful development of poly ADP-ribose polymerase (PARP) inhibitors for patients with mCRPC and mutations in DNA damage repair genes has added to the treatment armamentarium and improved personalized treatments for prostate cancer. Other promising therapeutic agents currently in clinical development include the radiotherapeutic 177-lutetium-prostate-specific membrane antigen (PSMA)-617 targeting PSMA-expressing prostate cancer and combinations of immunotherapy with currently effective treatment options for prostate cancer. Herein, we have highlighted the progress in systemic treatments for mCRPC and the promising agents currently in ongoing clinical trials.

Details

Title
Novel therapies are changing treatment paradigms in metastatic prostate cancer
Author
Powers, Eric; Karachaliou, Georgia Sofia; Kao, Chester; Harrison, Michael R; Hoimes, Christopher J; George, Daniel J; Armstrong, Andrew J; Zhang, Tian  VIAFID ORCID Logo 
Pages
1-13
Section
Review
Publication year
2020
Publication date
2020
Publisher
BioMed Central
e-ISSN
17568722
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1186/s13045-020-00978-z
ProQuest document ID
2461945496
Copyright
© 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.